Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment

Bennett Levitan, Michael Markowitz, Ateesha F. Mohamed, F. Reed Johnson, Larry Alphs, Leslie Citrome, John F P Bridges

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this study was to quantify patients' preferences related to benefits and risks of antipsychotic treatments for schizophrenia and to assess the relative importance of treatment attributes and adherence. Methods: Treatment-related preferences among U.S. residents with a self-reported physician diagnosis of schizophrenia were assessed via a discrete-choice experiment. Patients chose between competing hypothetical scenarios characterized by improvements in positive symptoms, negative symptoms, and social functioning; incidence of weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia; and medication formulation. Preferences were estimated by using a random-parameters logit model, and the impact of adherence was estimated with conditional logit models. Results: The final sample consisted of 271 patients. Complete improvement in positive symptoms was the most preferred outcome (relative importance score of 10.0), followed by elimination of hyperglycemia (3.6, 95% confidence interval [CI]=2.6-4.6), improvement in negative symptoms (3.0, CI=1.6-4.3), reduced weight gain (2.6, CI=1.2-4.0), avoidance of hyperprolactinemia (1.7, CI=.9-2.6), improved social functioning (1.5, CI=.4-2.5), and avoidance of EPS (1.0, CI=.3-1.8). Patients judged a daily pill superior to monthly injections (p

Original languageEnglish (US)
Pages (from-to)719-726
Number of pages8
JournalPsychiatric Services
Volume66
Issue number7
DOIs
StatePublished - Jul 1 2015

Fingerprint

Patient Preference
Schizophrenia
Confidence Intervals
Hyperprolactinemia
Hyperglycemia
Weight Gain
Therapeutics
Logistic Models
Antipsychotic Agents
Physicians
Injections
Incidence

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Levitan, B., Markowitz, M., Mohamed, A. F., Johnson, F. R., Alphs, L., Citrome, L., & Bridges, J. F. P. (2015). Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatric Services, 66(7), 719-726. https://doi.org/10.1176/appi.ps.201400188

Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment. / Levitan, Bennett; Markowitz, Michael; Mohamed, Ateesha F.; Johnson, F. Reed; Alphs, Larry; Citrome, Leslie; Bridges, John F P.

In: Psychiatric Services, Vol. 66, No. 7, 01.07.2015, p. 719-726.

Research output: Contribution to journalArticle

Levitan, B, Markowitz, M, Mohamed, AF, Johnson, FR, Alphs, L, Citrome, L & Bridges, JFP 2015, 'Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment', Psychiatric Services, vol. 66, no. 7, pp. 719-726. https://doi.org/10.1176/appi.ps.201400188
Levitan B, Markowitz M, Mohamed AF, Johnson FR, Alphs L, Citrome L et al. Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment. Psychiatric Services. 2015 Jul 1;66(7):719-726. https://doi.org/10.1176/appi.ps.201400188
Levitan, Bennett ; Markowitz, Michael ; Mohamed, Ateesha F. ; Johnson, F. Reed ; Alphs, Larry ; Citrome, Leslie ; Bridges, John F P. / Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment. In: Psychiatric Services. 2015 ; Vol. 66, No. 7. pp. 719-726.
@article{cbafe0e6556642f8876c3c6eb3f4b3bd,
title = "Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment",
abstract = "Objective: The objective of this study was to quantify patients' preferences related to benefits and risks of antipsychotic treatments for schizophrenia and to assess the relative importance of treatment attributes and adherence. Methods: Treatment-related preferences among U.S. residents with a self-reported physician diagnosis of schizophrenia were assessed via a discrete-choice experiment. Patients chose between competing hypothetical scenarios characterized by improvements in positive symptoms, negative symptoms, and social functioning; incidence of weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia; and medication formulation. Preferences were estimated by using a random-parameters logit model, and the impact of adherence was estimated with conditional logit models. Results: The final sample consisted of 271 patients. Complete improvement in positive symptoms was the most preferred outcome (relative importance score of 10.0), followed by elimination of hyperglycemia (3.6, 95{\%} confidence interval [CI]=2.6-4.6), improvement in negative symptoms (3.0, CI=1.6-4.3), reduced weight gain (2.6, CI=1.2-4.0), avoidance of hyperprolactinemia (1.7, CI=.9-2.6), improved social functioning (1.5, CI=.4-2.5), and avoidance of EPS (1.0, CI=.3-1.8). Patients judged a daily pill superior to monthly injections (p",
author = "Bennett Levitan and Michael Markowitz and Mohamed, {Ateesha F.} and Johnson, {F. Reed} and Larry Alphs and Leslie Citrome and Bridges, {John F P}",
year = "2015",
month = "7",
day = "1",
doi = "10.1176/appi.ps.201400188",
language = "English (US)",
volume = "66",
pages = "719--726",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "7",

}

TY - JOUR

T1 - Patients' preferences related to benefits, risks, and formulations of schizophrenia treatment

AU - Levitan, Bennett

AU - Markowitz, Michael

AU - Mohamed, Ateesha F.

AU - Johnson, F. Reed

AU - Alphs, Larry

AU - Citrome, Leslie

AU - Bridges, John F P

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Objective: The objective of this study was to quantify patients' preferences related to benefits and risks of antipsychotic treatments for schizophrenia and to assess the relative importance of treatment attributes and adherence. Methods: Treatment-related preferences among U.S. residents with a self-reported physician diagnosis of schizophrenia were assessed via a discrete-choice experiment. Patients chose between competing hypothetical scenarios characterized by improvements in positive symptoms, negative symptoms, and social functioning; incidence of weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia; and medication formulation. Preferences were estimated by using a random-parameters logit model, and the impact of adherence was estimated with conditional logit models. Results: The final sample consisted of 271 patients. Complete improvement in positive symptoms was the most preferred outcome (relative importance score of 10.0), followed by elimination of hyperglycemia (3.6, 95% confidence interval [CI]=2.6-4.6), improvement in negative symptoms (3.0, CI=1.6-4.3), reduced weight gain (2.6, CI=1.2-4.0), avoidance of hyperprolactinemia (1.7, CI=.9-2.6), improved social functioning (1.5, CI=.4-2.5), and avoidance of EPS (1.0, CI=.3-1.8). Patients judged a daily pill superior to monthly injections (p

AB - Objective: The objective of this study was to quantify patients' preferences related to benefits and risks of antipsychotic treatments for schizophrenia and to assess the relative importance of treatment attributes and adherence. Methods: Treatment-related preferences among U.S. residents with a self-reported physician diagnosis of schizophrenia were assessed via a discrete-choice experiment. Patients chose between competing hypothetical scenarios characterized by improvements in positive symptoms, negative symptoms, and social functioning; incidence of weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia; and medication formulation. Preferences were estimated by using a random-parameters logit model, and the impact of adherence was estimated with conditional logit models. Results: The final sample consisted of 271 patients. Complete improvement in positive symptoms was the most preferred outcome (relative importance score of 10.0), followed by elimination of hyperglycemia (3.6, 95% confidence interval [CI]=2.6-4.6), improvement in negative symptoms (3.0, CI=1.6-4.3), reduced weight gain (2.6, CI=1.2-4.0), avoidance of hyperprolactinemia (1.7, CI=.9-2.6), improved social functioning (1.5, CI=.4-2.5), and avoidance of EPS (1.0, CI=.3-1.8). Patients judged a daily pill superior to monthly injections (p

UR - http://www.scopus.com/inward/record.url?scp=84936165369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936165369&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.201400188

DO - 10.1176/appi.ps.201400188

M3 - Article

VL - 66

SP - 719

EP - 726

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 7

ER -